CDX Medical Technologies (CDX), a pioneer in extracorporeal membrane oxygenation (ECMO) pump innovation, today announced the successful close of its $2.5 million Series A funding round. The round was led by Joe Kiani, Founder of Masimo and a world-renowned health technology entrepreneur, with participation from leading industry executives and the CDX Board of Directors. Kiani, who also founded Willow Laboratories and co-founded Like Minded Labs, will join the CDX Board.

This investment enables CDX to complete regulatory testing, secure market approval and initiate commercialization.

Welcoming Joe to the Board, Co-CEO Dr. Gopal K. Chopra stated, "We are thrilled to have Joe on the CDX team. Joe brings a wealth of experience and insight into the world of respiratory care and intelligent medical devices. His investment and contributions at the Board level will significantly assist the company in creating a new market and disrupting respiratory care to the benefit of patients worldwide. Joe's enthusiasm for impactful innovation and his commitment to patient safety and care will be transformative."

Co-CEO Rick Smith added, "Joe's involvement brings the expertise to navigate the global landscape of medical devices and strategic insight into growing markets."

"ECMO is a lifesaving solution, but today it takes too much from our valued resources and therefore it's only provided to a few. CDX is revolutionizing ECMO by making it not just small and portable, but by practically automating it. The CDX platform will benefit respiratory failure patients worldwide in an area that has needed disruption," said Joe Kiani.

Dr. Hugh Cassiere, Director of Critical Care, Cardiac Services at South Shore University Hospital of Northwell Health and current chair of the FDA's Anesthesiology and Respiratory Therapy Devices panel, added, "CDX is providing a much-needed innovation where nothing exists. The company has demonstrated its commitment to innovation and incorporating the clinical need, and we are very excited to be a lead potential site for the commercial release."

CDX has long been at the forefront of clinical conversation around lung failure and lung recovery. Following extensive bench and in vivo testing, the company is preparing to submit its proprietary pump for regulatory approval for use in ECMO. The new funding will support completion of submission testing, early commercial development and team expansion.